New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:30 EDTSYNSynthetic reports preclinical data to support clinical development of mAb
Synthetic Biologics announced positive preclinical research findings for SYN-005, the company's proprietary monoclonal antibody, or mAb, combination therapy for treating Pertussis. In the second pertussis study in particular, SYN-005 was associated with favorable decreases in white blood cell counts within two days and the achievement of nearly normal levels within one week. Based on positive non-human primate and murine model findings, Synthetic Biologics has filed an additional patent application around pertussis antibodies, intends to move into cGMP manufacturing of SYN-005, and intends to file an Investigational New Drug application to support a Phase I clinical trial expected to initiate during the first half of 2015. The Company also intends to request an Orphan Drug designation for SYN-005 for the treatment of Pertussis.
News For SYN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
06:58 EDTSYNSynthetic Biologics initiates Phase 2a clinical trial of SYN-004
Subscribe for More Information
March 22, 2015
11:13 EDTSYNSynthetic Biologics has lunch meeting with Philadelphia Securities Association
Subscribe for More Information
March 19, 2015
09:20 EDTSYNOn The Fly: Pre-market Movers
Subscribe for More Information
06:58 EDTSYNSynthetic Biologics announces positive PK results from SYN-004 trials
Subscribe for More Information
March 16, 2015
14:03 EDTSYNSynthetic Biologics downgraded to Hold from Buy at Maxim
Maxim downgraded Synthetic Biologics to Hold following management's decision no to move SYN-005 for pertussis until funding is found, which creates another uncertainty regarding the timeline. Price target is $3.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use